Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system ...

Corbus Pharmaceuticals (CRBP) closed the last trading session at $53.60, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $82.67 indicates a 54.2% upside potential. The average comprises six short-term price targets ranging from a low of $76 to a high of $88, with a standard deviation of $4.27. While the lowest estimate indicates an increase of 41.8% from the current pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 (Sta ...

Exhibit 99.1 Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update • Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancer • CRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial cancer and other nectin-4 enriched tumors and is on schedule for completion in Q4 2024 • Cash runway extended throu ...

Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancer CRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial cancer and other nectin-4 enriched tumors and is on schedule for completion in Q4 2024 Cash runway extended through Q3 2027 with $147 million of cash & investments at June 30, 2024 NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Co ...

BTIG Virtual Biotechnology Conference Date: August 13-14, 2024 Format: Invitation only, one on one and small group investor meetings Note: Investors interested in attending and meeting with management should contact their Wedbush representatives. Forward-Looking Statements NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two invest ...

NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events. Wedbush PacGrow Healthcare Conference Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a d ...

Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow. More often than not, they will hunker down instead of taking on new, expensive debt. Here are three small-cap stocks that could soar to the top of the market. They posses strong tailwinds that an improved economy will reveal as ...

NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate, has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, F ...

NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First- In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will ...